$OKLO

Narayanadas Vivek sold $10K of OKLO

Narayanadas Vivek (General Counsel & Secretary) sold 238 shares of Oklo Inc. (OKLO) at $42.06 on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Narayanadas Vivek
Published Sep 9, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OKLO
Neutral
low confidence
Mentioned
$OKLO
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OKLONeutralLow
01

Why it matters

The transaction is small and pre‑arranged, unlikely to move the stock.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions could make the sale more material.

Relevance 2/10Novelty 5/10Timing: sale reported on 2026-09-08 (post‑market)

Background

SEC Form 4 filing discloses an insider transaction by Oklo's General Counsel.

Company-level read

Ticker impact

$OKLONeutralLow confidence
Context

Form 4 filing shows General Counsel sold 238 shares for $10,010 at $42.06 each.

Expected impact

negligible

Evidence & confidence

Sale size is tiny relative to float and disclosed via 10b5-1 plan.

Counterpoint

Insider sales sometimes precede negative news, but size here is trivial.

Key entities

  • Oklo Inc.

    Nuclear fuel developer listed on NASDAQ under OKLO.

  • Narayanadas Vivek

    General Counsel & Secretary of Oklo, reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SMRLowAI 8/10

NuScale Power Falls 7% as 10-Year Treasury Yield Climbs to 5.26%; Energy Fuels Drops 9%, Oklo Slides 5%

NuScale Power (SMR) fell 7% to $6.04, Energy Fuels (UUUU) dropped 9% to $8.43, and Oklo (OKLO) slid 5% to $30.11 as 10-year Treasury yields rose to 5.26%. The Global X Uranium ETF (URA) declined 4%, outpacing the broader market's 0.8% drop. Rising yields impact long-duration assets like nuclear developers, affecting both valuation and project financing costs.

$OKLOHigh

Oklo Launched Another $1 Billion Stock Sale. Here's How Much Dilution Shareholders Have Absorbed Since It Went Public.

Oklo (NYSE: OKLO), a nuclear energy company, launched a $1 billion stock sale on Sept. 11, adding to prior sales since its May 2024 SPAC merger. Outstanding shares increased 58% to 192.3 million, diluting early shareholders by 37%. Despite a 311% share price increase, Oklo's stock hit a 52-week low on Oct. 8, requiring more shares to raise the same capital.

$GOOGHighAI 8/10

Google Signed a Deal for Existing Reactors. So Why Did Oklo and NuScale Jump on the Constellation Energy News? The Read-Through Investors Are Missing.

Alphabet (GOOG, GOOGL) agreed to a 15-year and 20-year deal with Constellation Energy (CEG) for nuclear power, investing $4.3B in new capacity. Oklo (OKLO) and NuScale (SMR) shares also rose, despite no direct involvement. The companies develop small modular reactors (SMRs) for specific facilities, differing from Constellation's large-scale plants. Investors see broader nuclear energy growth, with SMRs expected to play a significant role by 2050, according to industry estimates.

$OKLOMed

Oklo (OKLO) Dropped, So What Is Driving Attention Now?

Oklo, a modular nuclear reactor company, focuses on selling long-term electricity contracts. It secured NRC approval for its Aurora design, has $1.6B cash, and partnerships with NVDA, META, and Switch. However, it reports $33M net loss, no revenue, and no operating plants. Market cap is $11B. Regulatory hurdles remain.

$OKLOMed

Oklo selected for DOE isotope production initiative

Oklo Inc. (NYSE:OKLO) was chosen by the U.S. Department of Energy to advance its Groves 2 Forge facility, focusing on producing lutetium-177 for cancer treatments. The project is part of the DOE’s initiative to boost domestic nuclear reactor development and isotope production. Oklo aims to transition from pilot to commercial-scale operations with regulatory approvals.